Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae584 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Nathaniel M Lewis und 56 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Oseltamivir, Influenza, Human, Antiviral Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, CDC HHS, NCIRD CDC HHS.
Abstract (Originalsprache)
Background
Clinical guidelines recommend initiation of antiviral therapy as soon as possible for patients hospitalized with confirmed or suspected influenza.
Methods
A multicenter US observational sentinel surveillance network prospectively enrolled adults (aged ≥18 years) hospitalized with laboratory-confirmed influenza at 24 hospitals during 1 October 2022–21 July 2023. A multivariable proportional odds model was used to compare peak pulmonary disease severity (no oxygen support, standard supplemental oxygen, high-flow oxygen/non-invasive ventilation, invasive mechanical ventilation, or death) after the day of hospital admission among patients starting oseltamivir treatment on the day of admission (early) versus those who did not (late or not treated), adjusting for baseline (admission day) severity, age, sex, site, and vaccination status. Multivariable logistic regression models were used to evaluate the odds of intensive care unit (ICU) admission, acute kidney replacement therapy or vasopressor use, and in-hospital death.
Results
A total of 840 influenza-positive patients were analyzed, including 415 (49%) who started oseltamivir treatment on the day of admission, and 425 (51%) who did not. Compared with late or not treated patients, those treated early had lower peak pulmonary disease severity (proportional adjusted odds ratio [aOR]: 0.60, 95% confidence interval [CI]: .49–.72), and lower odds of intensive care unit admission (aOR: 0.24, 95% CI: .13–.47), acute kidney replacement therapy or vasopressor use (aOR: 0.40, 95% CI: .22–.67), and in-hospital death (aOR: 0.36, 95% CI: .18–.72).
Conclusions
Among adults hospitalized with influenza, treatment with oseltamivir on day of hospital admission was associated reduced risk of disease progression, including pulmonary and extrapulmonary organ failure and death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.
- School of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
- Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Center for Research in Vaccines and Infections, Baylor Scott & White Health, Texas, USA.
- College of Medicine, Baylor University, Temple, Texas, USA.
- College of Medicine, Texas A&M University, Dallas, Texas, USA.
ORCID-Profile: Nathaniel M Lewis, Elizabeth J Harker, Lauren B Grant, Yuwei Zhu, Carlos G Grijalva, Paul W Blair, Adam S Lauring, Manju Gaglani, Shekhar Ghamande, Laurence W Busse, Ithan D Peltan, Samuel M Brown, David N Hager, Amira Mohamed, Akram Khan, Nida Qadir, Steven Y Chang, Nicholas M Mohr, Christopher Mallow, Vasisht Srinivasan, Ivana A Vaughn, Mayur Ramesh, Basmah Safdar, Jennifer DeCuir, Diya Surie, Mark W Tenforde, Timothy M Uyeki, Shikha Garg, Sascha Ellington, Wesley H Self
Förderung
- NIGMS NIH HHS
- CDC HHS
- NCIRD CDC HHS
- Centers for Disease Control and Prevention
- National Center for Immunization and Respiratory Diseases
- NIH
Zitieren
APA
Lewis, N. M., Harker, E. J., Grant, L. B., Zhu, Y., Grijalva, C. G., Chappell, J. D., Rhoads, J. P., Baughman, A., Casey, J. D., Blair, P. W., Jones, I. D., Johnson, C. A., Lauring, A. S., Gaglani, M., Ghamande, S., Columbus, C., Steingrub, J. S., Shapiro, N. I., Duggal, A., …, & Investigating Respiratory Viruses in the Acutely Ill (IVY) Network (2025). Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae584
Vancouver
Lewis NM, Harker EJ, Grant LB, Zhu Y, Grijalva CG, Chappell JD, et al. Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae584
BibTeX
@article{Lewis2025,
author = {Lewis, Nathaniel M and Harker, Elizabeth J and Grant, Lauren B and Zhu, Yuwei and Grijalva, Carlos G and Chappell, James D and Rhoads, Jillian P and Baughman, Adrienne and Casey, Jonathan D and Blair, Paul W and Jones, Ian D and Johnson, Cassandra A and Lauring, Adam S and Gaglani, Manju and Ghamande, Shekhar and Columbus, Cristie and Steingrub, Jay S and Shapiro, Nathan I and Duggal, Abhijit and Busse, Laurence W and Felzer, Jamie and Prekker, Matthew E and Peltan, Ithan D and Brown, Samuel M and Hager, David N and Gong, Michelle N and Mohamed, Amira and Exline, Matthew C and Khan, Akram and Hough, Catherine L and Wilson, Jennifer G and Mosier, Jarrod and Qadir, Nida and Chang, Steven Y and Ginde, Adit A and Martinez, Amanda and Mohr, Nicholas M and Mallow, Christopher and Harris, Estelle S and Johnson, Nicholas J and Srinivasan, Vasisht and Gibbs, Kevin W and Kwon, Jennie H and Vaughn, Ivana A and Ramesh, Mayur and Safdar, Basmah and Goyal, Anirudh and DeLamielleure, Lauren E and DeCuir, Jennifer and Surie, Diya and Dawood, Fatimah S and Tenforde, Mark W and Uyeki, Timothy M and Garg, Shikha and Ellington, Sascha and Self, Wesley H and Investigating Respiratory Viruses in the Acutely Ill (IVY) Network, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network},
title = {Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae584}
}
EUVIMED